Background: A key factor in the success of gout management is the long-term lowering of uricemia below predetermined targets (300 or 360μ mol/l). Monitoring of uricemia in gout patients is therefore important, and is presently done in the laboratory on plasma samples obtained after venous puncture. An accurate uric acid (UA) meter allowing rapid testing by the health care professionals and self-measurement by the patient should improve management of gout. Objectives: This study aimed to assess the reliability of immediate UA measurement in capillary blood samples obtained from fingertip puncture using the HumaSens Plus point-of-care meter (meter) compared with that of a standard laboratory assay (lab). Methods: Capillary UA levels were measured from 236 consenting diabetic patients using the commercially available HumaSens Plus UA meter (European Conformity marked and approved for EU market use). Each patient also had a plasma UA measurement in the biochemistry laboratory using an uricase automated colorimetric assay. Since the UA meter has a dynamic range of 180-1190μ mol/l, when the values were out-ranged (meter reading LO or HI), they were individually compared to corresponding plasma measurements. Agreement between capillary and plasma UA levels was assessed by Intraclass Correlation Coefficient (ICC) and Bland-Altman graphic representation. Best capillary UA threshold for detection of hyperuricemia (plasma UA>360μmol/l) was determined from a ROC curve, relationship between methods were identified by regression. Impact of potential confounding factors (biological parameters/treatments) was searched. A total of 206 paired measurements were required for estimation of an ICC of 0.80 with a precision of 0.10 at alpha risk of 0.05%. To better understand discrepancies between meter and lab, results were compared to reference plasma UA measurements by liquid chromatography-mass spectrometry (LC-MS) in a subgroup of 77 patients who gave complementary consent. Results: Fourteen capillary samples were read LO by the meter: 11 were confirmed by lab to be below 180μmol/l and 3 were above (189, 206 and 428μmol/l Background: Gout is a chronic, progressive, inflammatory disease characterised by elevated serum uric acid (sUA) levels (1). In Europe the prevalence of gout ranges from 0.9-2.5%, and is increasing (2). Published data indicate that gout is an independent risk factor for both all-cause and cardiovascular (CV)-related mortality (3, 4). Objectives: To conduct a systematic review to identify studies reporting the association between gout and mortality (all-cause and CV-related). Methods: Relevant publications were identified by interrogating electronic databases; Medline & MEDLINE In-Process, EMBASE and the Cochrane Library (accessed 3 May 2016). Eligibility criteria included adult patients with a definitive diagnosis of acute/chronic gout (self-reported/physician diagnosed), with no restriction on publication date, study design or geography. Results: Nineteen studies met the pre-defined inclusion criteria and were reviewed. The studies were conducted in: the US (n=8); Taiwan (n=5); Canada (n=3); Spain (n=1); Singapore (n=1); and the UK (n=1). In addition to patients having a diagnosis of acute/chronic gout, 6 of the 19 studies were conducted in the following patient subgroups: renal transplant (n=1); chronic kidney disease (n=2); patients with a recent acute myocardial infraction (n=2); and patients with heart failure (n=1). There were several consistent finding across the 19 studies: (i) gout was associated with an increase in both all-cause mortality (reported hazard ratios [HR] ranged from 1.13 to 2.37) and CV-related mortality (reported HR ranged from 1.10 to 3.88) compared with patients without gout; (ii) the increased risk in all-cause mortality was primarily driven by an increase in CV-related mortality; (iii) the increased mortality risk was higher in females than males. One study reported that the presence of tophi was independently associated with a higher risk of all-cause mortality. Notably one study reported that patients who received urate-lowering therapy (ULT) have a statistically significant lower all-cause mortality and CV-related mortality risk relative to patients who do not receive ULT. Conclusions: This systematic review confirms that gout is associated with an increased risk of all-cause and CV-related mortality; this was consistently reported across the eligible studies. The findings highlight the risk associated with gout and emphasise the need for appropriate treatment of this curable disease. Background: New Caledonia is a Pacific island of 270.000 inhabitants with mixed ethnicities, including Melanesians (39.1%) and Polynesians (10.2%) and people from European ancestry (27.2%). Objectives: To determine the prevalence of gout and hyperuricemia in the various ethnicities and to characterize associated factors. Methods: A 3-degree random sample of the population aged 18 to 60 years old was redressed according to the 2014 New Caledonia census. Face-to-face interviews were performed by trained nurses who used a predefined questionnaire along with planned physical measurements. All participants underwent capillary measurement of creatinine level (StatSensor) and all men and only women older
